Filing Details
- Accession Number:
- 0001104659-23-120804
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-11-22 17:00:50
- Reporting Period:
- 2023-11-20
- Accepted Time:
- 2023-11-22 17:00:50
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1722964 | Y-Mabs Therapeutics Inc. | YMAB | Pharmaceutical Preparations (2834) | 474619612 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1753224 | Thomas Gad | C/O Y-Mabs Therapeutics, Inc. 230 Park Avenue, Suite 3350 New York NY 10169 | Chief Business Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-11-20 | 75,000 | $5.30 | 490,032 | No | 4 | S | Indirect | By GAD Enterprises LLC |
| Common Stock | Disposition | 2023-11-21 | 75,000 | $5.31 | 415,032 | No | 4 | S | Indirect | By GAD Enterprises LLC |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | By GAD Enterprises LLC |
| No | 4 | S | Indirect | By GAD Enterprises LLC |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 60,000 | Indirect | By children |
| Common Stock | 90,500 | Direct |
Footnotes
- This transaction was executed in multiple trades at prices ranging from $5.2400 to $5.4800. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $5.2300 to $5.4900. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- Reporting Person is sole member of GAD Enterprises, LLC and the sole member and manager of GAD Management, LLC, the manager of GAD Enterprises, LLC, and as such Reporting Person has sole voting and dispositive power with respect to such shares.
- Represents shares owned by Reporting Person's children who are deemed to share Reporting Person's household.
- Represents 50,000 shares of Common Stock owned by Reporting Person as well as 40,500 restricted stock units ("RSUs") granted to the Reporting Person on January 17, 2023 pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU. The RSUs vest by 1/3 on each of January 17, 2024, January 17, 2025 and January 17, 2026 subject to the continuing employment of the Reporting Person on each vesting date.
Billionaire Hedge Funds
